News | January 29, 2018

Coronary CT Often Misinterpreted With Higher Rates of CAD

RSNA late-breaking trial showed core lab analysis of CTA classified significantly fewer patients as having significant CAD compared to site interpretation

Readers of cardiac computed tomography (CT) exams often over estimate the risk if coronary artery disease (CAD) according to a new core-lab analysis from the PROMISE Trial. #RSNA17, #RSNA2017, #SCCT

Readers of cardiac computed tomography (CT) exams often over estimate the risk if coronary artery disease (CAD) according to a new core-lab analysis from the PROMISE Trial. 

January 26, 2017 — Results from a core lab analysis from the PROMISE Trial on cardiac computed tomography (CT) were among three high-impact clinical trials presented at the 2017 Radiological Society of North America (RSNA) meeting that offered radiology practice-changing clinical research.

“Core Laboratory Versus Local Site Interpretation of Coronary CT Angiography (CTA): Association with Cardiovascular Events in the PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain),” presented by Michael T. Lu, M.D., and Jonathan A. Leipsic, M.D., investigates the concordance and relative prognostic value of central core laboratory versus local site interpretation for significant coronary artery disease.

In the PROMISE trial, 193 North American sites interpreted coronary CTA as part of the clinical evaluation of stable chest pain. CTA was also interpreted retrospectively by a central core lab blinded to clinical data, site interpretation, and outcomes. Concordance between core lab and site interpretation for significant CAD (greater than 50 percent luminal stenosis) was assessed.

The findings revealed that core lab interpretation of coronary CTA classified significantly fewer patients as having significant CAD compared to site interpretation, without a loss of predictive power for cardiovascular events.

This study was simultaneously published online in the journal Radiology.

RSNA highlighted two other key trials on breast imaging. One was a pivotal study of a new tool, opto-acoustic imaging, to diagnose breast masses. The other study showed how patient involvement in the decision process in cases of ductal carcinoma in situ (DCIS) influences quality of life following treatment.

 

Read about other Key RSNA 2017 Study Presentations, Trends and Video.

Related Content

Canon displays new CT technologies in its virtual SCCT 2020 booth.
News | CT Angiography (CTA) | July 06, 2020
Canon Medical Systems USA has created a virtual trade-show experience for its cardiovascular computed tomography (CT)
Two examples of CT myocardial perfusion (CTP) imaging assessment software. Canon is on the left and GE Healthcare is on the right. Both of these technologies have been around for a few years, but there have been an increasing amount of clinical data from studies showing the accuracy of the technology compared to nuclear imaging, the current stand of care for myocardial perfusion imaging, and cardiac MRI.

Two examples of CT myocardial perfusion (CTP) imaging assessment software. Canon is on the left and GE Healthcare is on the right. Both of these technologies have been around for a few years, but there has been an increasing amount of clinical data from studies showing the accuracy of the technology compared to nuclear imaging, the current standard of care for myocardial perfusion imaging, and cardiac MRI.

Feature | CT Angiography (CTA) | June 08, 2020 | Dave Fornell, Editor
Here is an overview of a few of the biggest technology advances in...
Two examples of CT myocardial perfusion (CTP) imaging assessment software. Canon is on the left and GE Healthcare is on the right. Both of these technologies have been around for a few years, but there have been an increasing amount of clinical data from studies showing the accuracy of the technology compared to nuclear imaging, the current stand of care for myocardial perfusion imaging, and cardiac MRI. #SCCT #perfusionimaging 

Two examples of CT myocardial perfusion (CTP) imaging assessment software. Canon is on the left and GE Healthcare is on the right. Both of these technologies have been around for a few years, but there have been an increasing amount of clinical data from studies showing the accuracy of the technology compared to nuclear imaging, the current stand of care for myocardial perfusion imaging, and cardiac MRI.

News | CT Angiography (CTA) | March 16, 2020
March 16, 2020 — The Society of Cardiovascular Computed Tomography (SCCT) released a new...
New ESC Guideline Provides Class 1 Recommendation for Coronary CTA
News | CT Angiography (CTA) | September 17, 2019
The European Society of Cardiology (ESC) published new ...
HeartFlow Announces FDA Clearance for HeartFlow Planner
Technology | CT Angiography (CTA) | September 12, 2019
HeartFlow Inc. has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non...
Gallery | CT Angiography (CTA) | August 08, 2019 | Dave Fornell, Editor
This is a photo essay of the ca...
Videos | CT Angiography (CTA) | August 08, 2019
This is a quick video example of a cardiac computed tomography (CT) exam showing a Medtronic CoreValve transcatheter
Videos | CT Angiography (CTA) | August 08, 2019
This is an example of an automated calcium scoring software to speed review of coronary artery calcium (CAC) scoring
Siemens Go.Top cardiovascular edition CT scanner with its detachable tablets used by the tech to control the scanner so they can stay at the patient's side longer. #SCCT19

Siemens Go.Top cardiovascular edition CT scanner with its detachable tablets used by the tech to control the scanner so they can stay at the patient's side longer. (Photo by Dave Fornell)

Feature | CT Angiography (CTA) | August 06, 2019 | Dave Fornell, Editor
There were several interesting new trends in cardiovascular computed tomography (CT) imaging at the 2019...